Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Erectile Dysfunction Device Business May Benefit From Viagra Alternatives

This article was originally published in The Gray Sheet

Executive Summary

American Medical Systems attributes its 48% annual growth rate in female incontinence revenue to a swift succession of 510(k) product clearances

You may also be interested in...



Litigation In Brief

J&J/Medtronic stent litigation: Supreme Court declines to review ruling awarding Johnson & Johnson/Cordis $271 mil. for infringement of stent patents, including those related to its Palmaz-Schatz('762), denying a writ of certiorari in the case. The U.S. Court of Appeals for the Federal Circuit had denied a rehearing in September 2003 after siding with J&J last August and remanded the case back to its original Wilmington, Del. district court (1"The Gray Sheet" Oct. 6, 2003, In Brief). Medtronic notes that the stents at issue are obsolete...

Litigation In Brief

J&J/Medtronic stent litigation: Supreme Court declines to review ruling awarding Johnson & Johnson/Cordis $271 mil. for infringement of stent patents, including those related to its Palmaz-Schatz('762), denying a writ of certiorari in the case. The U.S. Court of Appeals for the Federal Circuit had denied a rehearing in September 2003 after siding with J&J last August and remanded the case back to its original Wilmington, Del. district court (1"The Gray Sheet" Oct. 6, 2003, In Brief). Medtronic notes that the stents at issue are obsolete...

AMS’ CryoGen Purchase Anticipates Expanded HerOption Applications

American Medical Systems will seek to extend HerOption endometrial ablation technology for fibroid treatment following the firm's acquisition of CryoGen

Latest Headlines
See All
UsernamePublicRestriction

Register

MT018963

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel